How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

被引：8
|
作者：
Kiess, Ana P. [1 ]
O'Donoghue, Joseph [2 ]
Uribe, Carlos [3 ,4 ]
Bodei, Lisa [5 ]
Hobbs, Robert F. [1 ]
Hesterman, Jacob [6 ]
Kesner, Adam L. [2 ]
Sgouros, George [7 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, 401 N Broadway,Ste 1440, Baltimore, MD 21231 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY USA
[3] BC Canc, Funct Imaging, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada
[5] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY USA
[6] Ratio Therapeut Inc, Boston, MA USA
[7] Johns Hopkins Med Inst, Dept Radiol, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 15期
关键词：
RESISTANT PROSTATE-CANCER; NORMAL-TISSUE; NEUROENDOCRINE TUMORS; RADIONUCLIDE THERAPY; RADIATION-DOSIMETRY; LU-177-DOTATATE; TOLERANCE; TOXICITY; KIDNEY; PRRT;
D O I：
10.1200/JCO.23.01241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：9
相关论文
共 23 条
  • [1] A parallel phase I/II clinical trial design for combination therapies
    Huang, Xuelin
    Biswas, Swati
    Oki, Yasuhiro
    Issa, Jean-Pierre
    Berry, Donald A.
    BIOMETRICS, 2007, 63 (02) : 429 - 436
  • [2] Improving early phase oncology clinical trial design: The case for finding the optimal biological dose
    Phillips, Alan
    Mondal, Shalini
    PHARMACEUTICAL STATISTICS, 2023, 22 (04) : 739 - 747
  • [3] Maximum tolerated dose estimation by Biased coin design and stopping rule in Phase I clinical trial
    Jeon, Soyoung
    Kim, Dongjae
    KOREAN JOURNAL OF APPLIED STATISTICS, 2020, 33 (02) : 137 - 145
  • [4] The expected toxicity rate at the maximum tolerated dose in the standard Phase I cancer clinical trial design
    Kang, SH
    Ahn, C
    DRUG INFORMATION JOURNAL, 2001, 35 (04): : 1189 - 1199
  • [5] A PROPOSAL FOR A NEW PHASE-I CLINICAL-TRIAL DESIGN - PATIENT CHOICE DOSE COHORT
    DAUGHERTY, C
    RATAIN, M
    MICK, R
    SIEGLER, M
    CLINICAL RESEARCH, 1993, 41 (03): : A662 - A662
  • [6] Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding
    Yan, F.
    Thall, P. F.
    Lu, K. H.
    Gilbert, M. R.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 694 - 699
  • [7] The Expected Toxicity Rate at the Maximum Tolerated Dose in the Standard Phase I Cancer Clinical Trial Design
    Seung-Ho Kang
    Chul Ahn
    Drug information journal : DIJ / Drug Information Association, 2001, 35 : 1189 - 1199
  • [8] Rejoinder to "A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III"
    Chapple, Andrew G.
    Thall, Peter F.
    BIOMETRICS, 2019, 75 (02) : 389 - 391
  • [9] Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose
    Qiu, Yingjie
    Zhao, Yi
    Liu, Hao
    Cao, Sha
    Zhang, Chi
    Zang, Yong
    CONTEMPORARY CLINICAL TRIALS, 2023, 127
  • [10] A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination
    Wang, Ziqing
    Zhang, Jingyi
    Xia, Tian
    He, Ruyue
    Yan, Fangrong
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (04) : 582 - 595
123